Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 2/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17596020 | 1.00 | CTSK (0.61) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL18562066 | 1.00 | CTSK (0.61) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL25015110 | 1.00 | CTSK (0.61) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL15671593 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371979 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL3087516 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371978 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371977 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL7345607 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL7018649 | 0.88 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029214-A | Phospholipid drug conjugate and preparation method and application thereof | 上海弼领生物技术有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4721767-A1 | ANTI-B7-H3 ANTIBODY OR FRAGMENT THEREOF, AND ANTIBODY DRUG CONJUGATE TARGETING B7-H3 | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12589101-B2 | Cyclodextrin protein drug conjugates | REGENERON PHARMACEUTICALS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260053943-A1 | NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | FULGENT GENETICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4659809-A2 | STEROIDS AND PROTEIN-CONJUGATES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4656248-A2 | ANTI-C-MET ANTIBODY DRUG CONJUGATES | AbbVie Manufacturing Management Unlimited Company (IE) | 2025-12-03 | — | — | EP | disclosed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-4217398-B1 | ANTI-C-MET ANTIBODY DRUG CONJUGATES | ABBVIE MFG MANAGEMENT UNLIMITED COMPANY (IE) | 2025-09-24 | — | — | EP | disclosed |
| US-20150344521-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150274774-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2015-10-01 | — | — | US | disclosed |
| US-9145441-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9090653-B2 | Macrocyclic inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | CYPRALIS LIMITED (GB) | 2014-01-30 | — | — | US | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
| EP-0519748-B1 | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme | MERCK & CO INC (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5434248-A | Peptidyl derivatives as inhibitors of interleukin-1β converting enzyme | MERCK & CO., INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0519748-A2 | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme | MERCK & CO. INC. (US) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030221-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | CTSK 1762/4885CTSS 1084/4885PSENEN 3107/4885 |
| US-20150274774-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | CTSK 1762/4885CTSS 1084/4885PSENEN 3107/4885 |
| US-12589101-B2 | Cyclodextrin protein drug conjugates | SSB, CHP1, IAPP | CTSK 4224/4885CTSS 3258/4885PSENEN 1717/4885 |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DNPEP | CTSK 3343/4885CTSS 4178/4885PSENEN 323/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | CTSK 2559/4885CTSS 2100/4885PSENEN 3227/4885 |
| US-20260053943-A1 | NANOCOMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CD47, PBK, CD4 | CTSK 2555/4885CTSS 4393/4885PSENEN 2914/4885 |
| US-20150344521-A1 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, ZC3HAV1, HCCS | CTSK 1762/4885CTSS 1084/4885PSENEN 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.